Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Fortschr Neurol Psychiatr ; 91(12): 523-534, 2023 Dec.
Article in German | MEDLINE | ID: mdl-38081166

ABSTRACT

The third edition of the German National Clinical Practice Guideline for Depression emphasizes the significance of cardinal measures much more strongly than before. Low-threshold cardinal measures are an indispensable component of every depression treatment, regardless of severity and setting. They are suitable as a standalone treatment for mild and moderate depression. If inadequate improvement is observed, additional therapies should be supplemented. They should be implemented immediately after diagnosis to enhance the success rate.Regarding cardinal measures, among other things, comprehensive patient education in understandable language is essential. Patients with depressive disorders require guidance on structuring their day and building healthy activities. Patients with depression-related sleep disturbances benefit from sleep hygiene rules. Wake therapy constitutes an excellent and low-risk treatment method with immediate effect, which is a standard component of adequate depression treatment. Patients with a seasonal pattern of depression should be advised on light therapy. All patients should be encouraged to engage in regular physical activity with moderate intensity.


Subject(s)
Depression , Sleep Wake Disorders , Humans , Depression/therapy , Health Status , Psychotropic Drugs , Phototherapy
2.
Eur Neuropsychopharmacol ; 27(11): 1090-1109, 2017 11.
Article in English | MEDLINE | ID: mdl-28988944

ABSTRACT

In this article, we aimed to assess the efficacy of adjunctive administration of nutritional supplements to antidepressants by means of a systematic review and meta-analysis. The supplements included were inositol, vitamin D, folic acid, vitamin B12, S-adenosyl-L-methionine (SAMe), omega-3 polyunsaturated fatty acids (n-3 PUFA) and zinc. A structured database search (MEDLINE, EBSCO, CENTRAL, Web of Science) was performed using terms for the respective substances in conjunction with terms for depression and the mode of treatment ("add-on" OR "adjunctive" OR "augmentation"). Meta-analyses, randomized controlled trials (RCTs) and non-randomized comparative studies that investigated the supplements as an add-on in the treatment of clinically diagnosed MDD were included. Agents had to be added to an existing antidepressant regime (augmentation) or started simultaneously with the antidepressant (acceleration). For n-3 PUFAs, folic acid and zinc, new meta-analyses were performed as part of this work. Our meta-analyses of 10 articles on n-3 PUFAs and four on zinc support their efficacy. For folic acid, our meta-analysis does not support efficacy. For n-3 PUFAs, sensitivity analysis showed no difference between acceleration and augmentation designs, but significant differences between individuals with or without comorbidities. For the remaining substances, only a few RCTs were available. The preliminary data on inositol was negative, while one RCT for vitamin D demonstrated positive results. For vitamin B12 one and for SAMe two RCTs and a few open trials are available reporting positive and mixed results. To summarize, for most of the substances, the available data is not yet sufficient or inconclusive.


Subject(s)
Antidepressive Agents/therapeutic use , Depressive Disorder/therapy , Dietary Supplements , Clinical Trials as Topic , Humans
3.
Dtsch Arztebl Int ; 111(45): 766-75; quiz 775, 2014 Nov 07.
Article in English | MEDLINE | ID: mdl-25467053

ABSTRACT

BACKGROUND: The 12-month prevalence of depression in Europe is approximately 7%; depression becomes chronic in 15-25% of sufferers. One-third to one-half do not respond to an initial trial of drug therapy lasting several weeks. METHODS: Selective literature review, including consideration of the German National Disease Management Guideline Unipolar Depression. RESULTS: At the end of an initial trial of treatment with an antidepressant drug, usually lasting four weeks, its efficacy should be evaluated systematically. In case of non-response, the following options have been found useful: measurement of the serum drug level, dose escalation (but not for selective serotonin reuptake inhibitors [SSRIs]), lithium augmentation, the addition of a second-generation antipsychotic (atypical neuroleptic), and any one of several defined combinations of antidepressants. There is no empirical evidence for switching to another antidepressant. Electroconvulsive therapy is the most effective treatment for refractory depression. Cognitive behavioral therapy, interpersonal psychotherapy, psychoanalysis and psychodynamic psychotherapy have also been found useful. The cognitive behavioral analysis system of psychotherapy (CBASP) was developed specifically for the treatment of chronic depression. CONCLUSION: The structured application of treatments of documented efficacy, in a stepwise treatment algorithm that gives equal weight to drugs and psychotherapy, is the best way to prevent or overcome treatment resistance and chronification.


Subject(s)
Antidepressive Agents/administration & dosage , Cognitive Behavioral Therapy/methods , Critical Pathways/organization & administration , Depression/diagnosis , Depression/therapy , Electroshock/methods , Antipsychotic Agents/administration & dosage , Chronic Disease , Combined Modality Therapy/methods , Depression/psychology , Germany , Humans , Lithium Compounds/administration & dosage , Recurrence , Treatment Failure
4.
World J Biol Psychiatry ; 8(2): 67-104, 2007.
Article in English | MEDLINE | ID: mdl-17455102

ABSTRACT

These practical guidelines for the biological treatment of unipolar depressive disorders in primary care settings were developed by an international Task Force of the World Federation of Societies of Biological Psychiatry (WFSBP). They embody the results of a systematic review of all available clinical and scientific evidence pertaining to the treatment of unipolar depressive disorders and offer practical recommendations for general practitioners encountering patients with these conditions. The guidelines cover disease definition, classification, epidemiology and course of unipolar depressive disorders, and the principles of management in the acute, continuation and maintenance phase. They deal primarily with biological treatment (including antidepressants, other psychopharmacological and hormonal medications, electroconvulsive therapy, light therapy).


Subject(s)
Antidepressive Agents/therapeutic use , Depressive Disorder/therapy , Electroconvulsive Therapy , Phototherapy , Antidepressive Agents/adverse effects , Antidepressive Agents/classification , Depressive Disorder/classification , Depressive Disorder/diagnosis , Depressive Disorder/epidemiology , Drug Interactions , Evidence-Based Medicine , Family Practice , Humans , Long-Term Care , Patient Care Team , Phytotherapy , Psychotropic Drugs/adverse effects , Psychotropic Drugs/classification , Psychotropic Drugs/therapeutic use , Referral and Consultation
SELECTION OF CITATIONS
SEARCH DETAIL